Site icon Phillips Ormonde Fitzpatrick | Patents, Trade Marks & IP Law

Evolva hits sweet spot for ‘sufficiency’ under new Act

On 15 April 2013 the ‘bar was raised’ on the Patents Act 1990.  While the law relating to sufficiency changed, there has been very little guidance as to how this change would be applied. Evolva SA [2017] APO 57 now provides some clarity as to the level of detail required in a specification.

Background

Evolva SA filed for a patent for a new way to make sugar-based sweeteners (known as mogrosides) by use of an enzyme.  The process involved contacting the starting materials with one of five specified enzymes or a polypeptide with “at least 90% sequence identity” to one of the specified enzymes, which during examination was deemed to be too broad and insufficiently supported.

This decision, which found in favour of Evolva SA, illustrates the type of information required to be disclosed to sufficiently support claims of broader scope than the illustrative examples provided.

The decision

One of the Delegate’s main considerations was whether or not a “research programme” would be required to assess whether a polypeptide, which was 90% identical to one of the specified polypeptides, would be effective in performing the invention. If so, then there would be insufficient support for the claims.

In finding for the applicant, the Delegate noted:

Conclusions

This case highlights the need for a specification to provide enough detail about an invention for a skilled person to plausibly work the invention. For complicated technologies, consideration should be given to outlining plausible ways of working the aspects of the invention, without undue burden and across the full scope of the claims, to guard against any support objections.

Exit mobile version